Fresenius Medical Care AG & Co KGaA logo

Fresenius Medical Care AG & Co KGaANYSE: FMS

Profile

Sector:

Healthcare

Country:

Germany

IPO:

17 September 1996

Next earnings report:

05 November 2024

Last dividends:

17 May 2024

Next dividends:

N/A
$11.28 B
-45%vs. 3y high
93%vs. sector
-25%vs. 3y high
35%vs. sector
-48%vs. 3y high
35%vs. sector
-46%vs. 3y high
14%vs. sector

Price

pre-market | 30 min ago
$19.22-$0.03(-0.16%)
$5.13 B$5.35 B
$5.13 B$201.35 M

Analysts recommendations

Institutional Ownership

FMS Latest News

Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
zacks.com22 October 2024 Sentiment: POSITIVE

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
prnewswire.com21 October 2024 Sentiment: POSITIVE

A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.

Fresenius Medical Care: Let's Look At The Upside
seekingalpha.com04 October 2024 Sentiment: POSITIVE

Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
zacks.com03 October 2024 Sentiment: POSITIVE

Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.

Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
zacks.com27 September 2024 Sentiment: POSITIVE

FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.

Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
zacks.com09 September 2024 Sentiment: POSITIVE

FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.

Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
prnewswire.com04 September 2024 Sentiment: POSITIVE

Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience WALTHAM, Mass. , Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers.

Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
zacks.com27 August 2024 Sentiment: POSITIVE

FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
zacks.com30 July 2024 Sentiment: POSITIVE

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company?

Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
prnewswire.com30 July 2024 Sentiment: POSITIVE

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target range Further divestitures closed as execution of portfolio optimization program continues Net financial debt and net leverage ratio further improved FY 2024 outlook confirmed BAD HOMBURG, Germany , July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG.

  • 1(current)
  • 2
  • 3

What type of business is Fresenius Medical Care AG & Co KGaA?

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

What sector is Fresenius Medical Care AG & Co KGaA in?

Fresenius Medical Care AG & Co KGaA is in the Healthcare sector

What industry is Fresenius Medical Care AG & Co KGaA in?

Fresenius Medical Care AG & Co KGaA is in the Medical Care Facilities industry

What country is Fresenius Medical Care AG & Co KGaA from?

Fresenius Medical Care AG & Co KGaA is headquartered in Germany

When did Fresenius Medical Care AG & Co KGaA go public?

Fresenius Medical Care AG & Co KGaA initial public offering (IPO) was on 17 September 1996

What is Fresenius Medical Care AG & Co KGaA website?

https://www.freseniusmedicalcare.com

Is Fresenius Medical Care AG & Co KGaA in the S&P 500?

No, Fresenius Medical Care AG & Co KGaA is not included in the S&P 500 index

Is Fresenius Medical Care AG & Co KGaA in the NASDAQ 100?

No, Fresenius Medical Care AG & Co KGaA is not included in the NASDAQ 100 index

Is Fresenius Medical Care AG & Co KGaA in the Dow Jones?

No, Fresenius Medical Care AG & Co KGaA is not included in the Dow Jones index

When was Fresenius Medical Care AG & Co KGaA the previous earnings report?

No data

When does Fresenius Medical Care AG & Co KGaA earnings report?

The next expected earnings date for Fresenius Medical Care AG & Co KGaA is 05 November 2024